$188 Million is the total value of Asymmetry Capital Management, L.P.'s 24 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 79.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $15,703,000 | – | 177,741 | +100.0% | 8.34% | – |
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $14,829,000 | +442.6% | 137,610 | +451.6% | 7.87% | +379.1% |
| UNH | New | UNITEDHEALTH GROUP INC | $13,479,000 | – | 26,844 | +100.0% | 7.16% | – |
| ABBV | New | ABBVIE INC | $12,788,000 | – | 94,448 | +100.0% | 6.79% | – |
| IQV | New | IQVIA HOLDINGS INC | $12,503,000 | – | 44,314 | +100.0% | 6.64% | – |
| CNC | New | CENTENE CORP | $12,216,000 | – | 148,254 | +100.0% | 6.48% | – |
| BLU | Buy | BELLUS HEALTH INC | $10,310,000 | +56.5% | 1,280,757 | +19.4% | 5.47% | +38.2% |
| CYTK | Sell | CYTOKINETICS INC | $10,257,000 | +16.5% | 225,032 | -8.6% | 5.44% | +2.9% |
| JNJ | New | JOHNSON & JOHNSON | $9,538,000 | – | 55,755 | +100.0% | 5.06% | – |
| NTRA | New | NATERA INC | $9,495,000 | – | 101,674 | +100.0% | 5.04% | – |
| FOLD | Buy | AMICUS THERAPEUTICS INC | $8,278,000 | +32.6% | 716,709 | +9.6% | 4.39% | +17.0% |
| ARGX | New | ARGENX SE - ADRadr | $7,312,000 | – | 20,881 | +100.0% | 3.88% | – |
| KURA | Buy | KURA ONCOLOGY INC | $7,032,000 | +93.2% | 502,275 | +158.5% | 3.73% | +70.6% |
| APLS | New | APELLIS PHARMACEUTICALS INC | $6,593,000 | – | 139,445 | +100.0% | 3.50% | – |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $6,436,000 | -13.4% | 43,876 | +4.5% | 3.42% | -23.5% |
| ISEE | Buy | IVERIC BIO INC | $6,287,000 | +8.9% | 375,989 | +5.8% | 3.34% | -3.8% |
| QTRX | Sell | QUANTERIX CORP | $6,072,000 | -24.7% | 143,204 | -11.6% | 3.22% | -33.5% |
| ITOS | Buy | ITEOS THERAPEUTICS INC | $4,877,000 | +215.3% | 104,755 | +82.9% | 2.59% | +178.4% |
| Sell | DICE MOLECULES HOLDINGS ORD | $4,687,000 | -48.0% | 185,201 | -32.7% | 2.49% | -54.1% | |
| AVDL | Sell | AVADEL PHARMACEUTICALS PLCadr | $2,983,000 | -35.8% | 369,134 | -22.2% | 1.58% | -43.3% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $2,886,000 | -33.7% | 198,493 | -17.9% | 1.53% | -41.4% |
| PMVP | Sell | PMV PHARMACEUTICALS INC | $2,256,000 | -25.0% | 97,680 | -3.2% | 1.20% | -33.7% |
| RGLS | Buy | REGULUS THERAPEUTICS INC | $860,000 | -11.2% | 2,731,044 | +94.9% | 0.46% | -21.5% |
| BLSA | Sell | BCLS ACQUISITION CORP- CL A | $699,000 | -4.2% | 71,372 | -2.6% | 0.37% | -15.5% |
| LRMR | Exit | LARIMAR THERAPEUTICS INC | $0 | – | -34,943 | -100.0% | -0.24% | – |
| GMTX | Exit | GEMINI THERAPEUTICS | $0 | – | -284,079 | -100.0% | -0.69% | – |
| Exit | AVALO THERAPEUTICS INC | $0 | – | -534,621 | -100.0% | -0.70% | – | |
| RNA | Exit | AVIDITY BIOSCIENCES INC | $0 | – | -126,116 | -100.0% | -1.87% | – |
| BAX | Exit | BAXTER INTERNATIONAL INC | $0 | – | -61,570 | -100.0% | -2.98% | – |
| KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -89,071 | -100.0% | -3.14% | – |
| AZN | Exit | ASTRAZENECA PLC-SPONS ADRadr | $0 | – | -116,242 | -100.0% | -4.20% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -215,985 | -100.0% | -4.83% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -150,001 | -100.0% | -5.37% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -229,117 | -100.0% | -6.10% | – |
| HOLX | Exit | HOLOGIC INC | $0 | – | -138,884 | -100.0% | -6.16% | – |
| PODD | Exit | INSULET CORP | $0 | – | -36,732 | -100.0% | -6.28% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -83,737 | -100.0% | -6.31% | – |
| ALKS | Exit | ALKERMES PLC | $0 | – | -373,382 | -100.0% | -6.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-01-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CENTENE CORP | 21 | Q4 2021 | 10.7% |
| UNITEDHEALTH GROUP INC | 21 | Q4 2021 | 7.2% |
| AMICUS THERAPEUTICS INC | 20 | Q4 2021 | 8.0% |
| PTC THERAPEUTICS INC | 19 | Q3 2021 | 13.8% |
| AERIE PHARMACEUTICALS INC | 16 | Q4 2019 | 9.9% |
| JAZZ PHARMACEUTICALS PLC | 15 | Q2 2021 | 10.2% |
| BIO-RAD LABRATORIES | 13 | Q2 2021 | 6.3% |
| NEVRO CORP | 12 | Q3 2018 | 7.2% |
| NEUROCRINE BIOSCIENCES INC | 12 | Q4 2018 | 6.5% |
| NUCANA PLC-ADR | 12 | Q4 2020 | 2.6% |
View Asymmetry Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-01-19 |
| 13F-HR | 2021-11-04 |
| 13F-HR | 2021-07-28 |
| 13F-HR | 2021-05-11 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-06 |
| 13F-HR | 2020-05-13 |
| 13F-HR | 2020-02-12 |
| 13F-HR | 2019-11-12 |
View Asymmetry Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.